MAM
UK TV ad market reached record high in 2013
MUMBAI: According to last year’s complete revenue figures released by Thinkbox – compiled on the basis of figures provided by UK’s commercial broadcasters – the total TV advertising revenue in UK rose 3.5 per cent in 2013 to ?4.63 billion ($7.75 billion).
Last year marked the fourth consecutive year that TV ad revenue had growth in the UK. TV ad investment is forecast to increase again this year, boosted by the World Cup in Brazil. The Advertising Association/Warc predicts growth in revenue for the TV ad market of six per cent in 2014.
There were 737 new or returning advertisers to TV for the year, accounting for two per cent of total TV ad revenues. TV advertising prices for the year were also the cheapest on record, some 38.5 per cent less expensive than 20 years ago.
Commercial impressions (the number of TV ads watched at normal speed) during 2013 were up 1.6 per cent on 2012, and have grown by 10.4 per cent over the last five years. The average viewer watched 47 ads a day. This is four ads more a day than five years ago. Collectively UK watched an average of 2.8 billion ads a day in the first half of the year.
MAM
Beacon Group appoints Dr Rajesh Patel as Group CEO
36-year healthcare veteran to lead Beacon Diagnostics, Vector Biotek, Biogeny.
MUMBAI: A new chief, a fresh diagnosis and a sharper prescription for growth. Beacon Group has appointed Dr Rajesh Patel as its Group Chief Executive Officer, effective April 1, 2026, signalling a decisive push to scale its presence in the diagnostics and IVD space. Patel steps into the role with 36 years of experience across the healthcare and diagnostics industry, bringing a career shaped by leadership roles spanning sales, marketing, business development and operational strategy. His mandate is both expansive and precise: to steer the group’s overall strategic direction while tightening coordination across its three core entities Beacon Diagnostics, Vector Biotek and Biogeny Diagnostics.
In practical terms, that means driving cross-company synergies, accelerating market expansion and strengthening organisational capability areas increasingly critical as diagnostic players compete for scale in a fragmented yet rapidly evolving healthcare ecosystem. The group is positioning itself to capture unmet demand across chain laboratories, key accounts and standalone labs, segments that remain underserved despite growing diagnostic needs.
The appointment comes at a time when the In Vitro Diagnostics (IVD) sector in India is entering a more competitive and innovation-led phase, with companies focusing not just on product pipelines but also on service delivery, integration and customer-centric models. Beacon’s leadership appears to be betting that Patel’s execution-focused approach can help translate ambition into operational momentum.
Welcoming the appointment, Chairman Dr D K Joshi described Patel’s induction as a strategic move aligned with the group’s long-term vision, emphasising the role of leadership depth in navigating the next phase of growth.
For Beacon Group, the message is clear, in a sector where precision matters, leadership is the new differentiator—and this appointment is intended to set the tone for what comes next.
